News Release Details
Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the fourth quarter of fiscal year 2022 before the market opens on Friday, March 31, 2023, rather than as previously announced to allow additional time to complete its financial statements. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
To participate in the conference call, dial 1-833-636-0497 (domestic) or +1-412-902-4241 (international) and refer to the Bioventus, Inc. Conference Call.
A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until March 30, 2024.
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Inquiries: